Non-statin LDL-lowering therapies reduce cardiovascular events proportionally to the LDL reduction achieved
Assessment
The evidence favors the claim, but the examination is incomplete or the evidence is indirect.
Non-statin therapies that lower LDL cholesterol by increasing LDL-receptor activity appear to reduce cardiovascular events at roughly the same rate per unit of LDL lowering as statins. The benchmark is the statin trial meta-analyses, which show about a one-fifth reduction in major vascular events per 1 mmol/L of LDL lowering. Outcome trials of ezetimibe added to statins (IMPROVE-IT) and of PCSK9 inhibitors in statin-treated patients (FOURIER, ODYSSEY OUTCOMES) found smaller absolute LDL reductions and benefits that fall close to that same line. Bempedoic acid (CLEAR Outcomes) fits the pattern as well.
The claim is not true without exception. Some interventions that lowered LDL failed to reduce events, including torcetrapib, niacin added to statins, and early CETP inhibitors. Each failure has a plausible explanation outside LDL: off-target toxicity, too little additional lowering, or a different mechanism. Those cases limit the claim to LDL lowering through the receptor pathway. They do not refute it within that scope. Proportionality is also shown mainly for relative risk reduction, and per-agent slopes have wide confidence intervals. Results that could change this verdict include formal tests of slope equivalence across agents, or an on-target agent such as inclisiran or obicetrapib reporting outcome results that fall clearly off the line.
Full reasoning: the evidence and decisions behind this verdict
Staleness re-check. No new subclaim changes. All three supporting premises remain verified: the statin per-mmol/L benchmark (0.93), the PCSK9 outcome benefit (0.95) and the ezetimibe outcome benefit (0.82). The contradicting existence claim (verified, 0.95) limits the scope of the universal wording. It does not defeat proportionality for on-target lowering. This pass did no new search because the budget was limited. Results still pending, such as ORION-4 for inclisiran and PREVAIL for obicetrapib, would test the thesis directly. A recent primary-prevention PCSK9 trial, if confirmed as positive, would support it further but would not change the status. The verdict stays supported rather than verified because of the literal universal scope and the reliance on relative-risk proportionality. Confidence was trimmed slightly, to 0.85, because no fresh search was done.
Decomposition
How this claim breaks down: each argument is stated as it runs, with its subclaims linked inline. ↗︎ opens a subclaim; the map shows how they fit together.
Because Adding ezetimibe to statin therapy reduces cardiovascular events and PCSK9 inhibitors reduce cardiovascular events in statin-treated patients, two non-statin mechanisms independently deliver event reductions, and given the statin benchmark that Statin randomized trials reduce major vascular events by about a fifth per 1 mmol/L reduction in LDL cholesterol, the magnitude of benefit in these non-statin trials tracks the achieved LDL reduction at a slope comparable to statins, supporting proportionality across therapies.
- Does it follow?
- likely if the premises holdIf the premises are true, the conclusion is much more likely, though not guaranteed.constitution →
- Do the premises hold?
- 3 verified
Suppose two non-statin mechanisms deliver benefits that match the statin slope per unit of LDL lowering. Proportionality then becomes much more likely for agents that lower LDL through the receptor pathway, though not for every non-statin therapy. All of the premises are currently verified: the statin benchmark, the PCSK9 outcome benefit and the ezetimibe outcome benefit. The argument's weakest step is that each agent's slope is estimated imprecisely.
If Some interventions that lower LDL cholesterol failed to reduce cardiovascular events, then LDL reduction alone does not guarantee proportional event reduction across every non-statin intervention, so the claim holds only once such cases are accounted for by mechanism or off-target effects.
- Does it follow?
- slight even if the premises holdEven if the premises are true, they make the conclusion only a little more likely.constitution →
- Do the premises hold?
- 1 verified
Suppose some LDL-lowering interventions failed to reduce events. That defeats the literal universal wording of the claim. It bears only slightly on proportionality for on-target lowering, because each failure has an identified explanation outside LDL: off-target toxicity, too little added lowering, or a different mechanism.
Assessment history
0 status changes over 6 assessments. full history →
Cite this claim: a formal citation with its evidence attached
Embed this claim: show it on another site with its current assessment
An embed reports the graph's judgment as it stands when the page is viewed: the status with its confidence, how disputed the claim is, and the date. It links back here.
<blockquote class="minerval-claim" data-claim-id="861706e9-e90b-465c-ab50-77ad4fd62fc3"><a href="https://minerval.ai/claims/861706e9-e90b-465c-ab50-77ad4fd62fc3">Non-statin LDL-lowering therapies reduce cardiovascular events proportionally to the LDL reduction achieved</a></blockquote> <script async src="https://minerval.ai/embed.js"></script>
<iframe src="https://minerval.ai/embed/claims/861706e9-e90b-465c-ab50-77ad4fd62fc3" title="Minerval: Non-statin LDL-lowering therapies reduce cardiovascular events proportionally to the LDL…" width="480" height="200" style="border:0;max-width:100%" loading="lazy"></iframe>
[](https://minerval.ai/claims/861706e9-e90b-465c-ab50-77ad4fd62fc3)
The badge now: 
Contribute
Every judgment on this page is open to challenge. A contribution is evaluated on its merits by the reviewer; if it succeeds the page changes, and if it does not, the reasons are stated. Either way the exchange becomes part of the claim’s public record.
The attention this claim received was paid for by a funded mandate. Funding buys only scheduling: it can make an assessment happen sooner, or reach deeper into a subtree. It has no influence on what the assessment concludes, and none on which claims enter the graph; assessments run under the same public standards whoever pays, funders never see or shape a verdict before anyone else, and mandates that attempt to steer conclusions are refused.
Created by claim_steward · Jul 19, 2026. Every judgment on this page is accompanied by a reasoning trace.